STOCK TITAN
  1. Home
  2. News
  3. ARWR

Arrowhead Research Corporation - ARWR STOCK NEWS

Welcome to our dedicated page for Arrowhead Research Corporation news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Research Corporation stock.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is a leading clinical-stage biotechnology company dedicated to developing innovative medicines that address intractable diseases through gene silencing. The company utilizes an extensive array of RNA chemistries and efficient delivery systems to harness the power of RNA interference (RNAi) mechanisms. This approach allows for the rapid, deep, and durable knockdown of target genes, thereby reducing the production of specific proteins that cause diseases.

Arrowhead's groundbreaking therapies are at the forefront of genetic-based treatments, presenting potential life-changing solutions for patients. Notable among their technologies is the Targeted RNAi Molecule (TRiMTM) platform. This platform employs ligand-mediated delivery for tissue-specific targeting while maintaining structural simplicity. The TRiMTM platform is built upon over a decade of research in actively targeted drug delivery, offering advantages such as simplified manufacturing processes and enhanced specificity.

The company's diverse portfolio includes promising treatments for conditions such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular diseases. Arrowhead is continuously engaged in advancing its clinical programs and forging strategic partnerships to bring its novel therapies to market.

With headquarters in Pasadena, California, Arrowhead Pharmaceuticals remains committed to transforming the landscape of genetic medicine and improving patient outcomes worldwide. Their dedication to scientific innovation and patient care positions them as a pivotal player in the biotechnology sector.

News

Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences

Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is set to participate in upcoming events like TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. The company will engage in Fireside Chat Presentations on March 6 and March 13, 2024, respectively. Interested parties can access presentation materials on the Arrowhead website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
conferences
-
News

Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results

Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (ARWR) announced its fiscal 2024 Q1 results, revealing a net loss of $132.9 million, a significant increase from the previous year. The company is focusing on cardiometabolic and pulmonary verticals, with plans to reduce operating cash burn by $100 million. They also terminated development of two programs, ARO-SOD1 and HZN-457, and strengthened their balance sheet through a $450 million stock offering. Financially, the company's cash, cash equivalents, and restricted cash decreased to $58.2 million from $110.9 million in the previous quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
earnings
-
News

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results

Rhea-AI Summary
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will host a webcast and conference call on February 6, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal first quarter ended December 31, 2023. Investors may access a live audio webcast on the Company's website. A replay of the webcast will be available. For analysts that wish to participate in the conference call, please register to receive the dial-in number and a personalized PIN code.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
conferences earnings
News

Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million

Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (ARWR) closed an underwritten registered offering of 15,790,000 shares of its Common Stock at $28.50 per share, generating approximately $450.0 million in gross proceeds. The company intends to allocate the net proceeds for research and development, general corporate expenses, and working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.9%
Tags
none
-
News

Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock

Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announces the pricing of an underwritten registered offering of 15,790,000 shares of its common stock at $28.50 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
offering
-
News

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) approved 'inducement' grants to 32 new employees, entitling them to receive up to 53,700 restricted stock units outside the stockholder-approved equity incentive plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
News

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease

Rhea-AI Summary
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, an investigational RNA interference therapeutic for complement mediated renal disease, such as IgAN. ARO-CFB aims to reduce hepatic expression of complement factor B, a key player in the activation of the alternative complement pathway. Pending clearance, Arrowhead intends to proceed with AROCFB-1001, a Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-CFB in up to 66 healthy volunteers and patients with complement mediated kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
clinical trial
-
News

Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is set to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 8:15 a.m. PT. The presentation will be available via webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.23%
Tags
conferences
-
News

Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results

Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced financial results for fiscal year 2023, including revenue of $240.7 million, operating loss of $205 million, and net loss of $209.3 million. The company presented positive Phase 2 clinical data for plozasiran and zodasiran, hosted a webinar featuring lipid and lipoprotein disorder experts, and completed encouraging chronic GLP toxicology for pulmonary candidates. Additionally, Arrowhead filed for regulatory clearance to initiate a Phase 1/2a study of ARO-DM1 for patients with type 1 myotonic dystrophy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.85%
Tags
earnings
News

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Rhea-AI Summary
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, an RNA interference therapeutic for type 1 myotonic dystrophy (DM1). ARO-DM1 aims to reduce the expression of the dystrophia myotonica protein kinase (DMPK) gene, addressing the lack of approved disease-modifying therapy for DM1. The company's Chief of Discovery and Translational Medicine, James Hamilton, M.D., MBA, highlighted the potential of ARO-DM1 in improving multiple symptoms, including muscle strength and function, for patients with DM1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
clinical trial

FAQ

What is the current stock price of Arrowhead Research Corporation (ARWR)?

The current stock price of Arrowhead Research Corporation (ARWR) is $19.63 as of December 24, 2024.

What is the market cap of Arrowhead Research Corporation (ARWR)?

The market cap of Arrowhead Research Corporation (ARWR) is approximately 2.4B.

What is the primary focus of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals focuses on developing gene-silencing therapies to treat intractable diseases by targeting the genes that cause them.

What is RNA interference (RNAi)?

RNA interference (RNAi) is a natural mechanism in living cells that inhibits the expression of specific genes, thereby affecting the production of certain proteins.

What is the TRiMTM platform?

The TRiMTM platform is Arrowhead's targeted RNAi molecule technology that uses ligand-mediated delivery for tissue-specific targeting, designed to simplify manufacturing and improve therapeutic precision.

Which diseases does Arrowhead Pharmaceuticals address?

Arrowhead's treatments target diseases such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Where is Arrowhead Pharmaceuticals headquartered?

Arrowhead Pharmaceuticals is headquartered in Pasadena, California.

What are the latest developments at Arrowhead Pharmaceuticals?

For the latest news and developments, visit Arrowhead Pharmaceuticals' official website or check recent press releases and updates.

How does Arrowhead's technology benefit patients?

Arrowhead's RNAi-based therapies aim to reduce the production of proteins that cause diseases, offering potential life-changing treatments for patients.

What are some advantages of the TRiMTM platform?

The TRiMTM platform's advantages include simplified manufacturing processes and enhanced tissue-specific targeting.

Is Arrowhead publicly traded?

Yes, Arrowhead Pharmaceuticals is publicly traded on the NASDAQ under the ticker symbol ARWR.

How can I invest in Arrowhead Pharmaceuticals?

You can invest in Arrowhead Pharmaceuticals by purchasing shares through a stockbroker or an online trading platform. The company's ticker symbol is ARWR.

Stock ARWR logo
Arrowhead Research Corporation

Nasdaq:ARWR

ARWR Rankings

#1826 Ranked by Market Cap
N/A Ranked by Dividends

ARWR Stock Data

2.44B
118.74M
4.47%
79.71%
7.6%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PASADENA